Evidence map›Paper›PMID 33486609›Full record

ReviewAAPS PharmSciTech2021

Emerging Nanomedicines for the Treatment of Atopic Dermatitis.

Khushali Parekh, Tejal A Mehta, Namdev Dhas, Pavan Kumar, Amirali Popat

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in AAPS PharmSciTech, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Novel drug delivery systems in topical treatment of atopic dermatitis.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Khushali ParekhDepartment of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, 382481, India.
Tejal A MehtaDepartment of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, 382481, India. tjshah3@gmail.com.
Namdev DhasDepartment of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, 382481, India.
Pavan KumarDr. Reddy's Laboratories Ltd., Hyderabad, India.
Amirali PopatSchool of Pharmacy, The University of Queensland, Woolloongabba, 4102, Australia.
Nirma University · INDr. Reddy's Laboratories (India) · INUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, the prevalence of Atopic dermatitis (AD) is significantly increasing and affecting around 20% of population including children. Complex interactions amongst abnormality in epidermal barrier function, environment, infectious agents and immunological defects are considered as key factors in the pathogenesis of AD. Although the role of oxidative stress has been studied in some skin diseases, investigation of the same in AD is intermittent. Calcineurin inhibitors and/or topical corticosteroids are currently available; however, it causes atrophy of the skin, burning sensation, and systemic side effects which leads to poor patient compliance. These limitations provoke the strong need to develop an innovative approach in managing AD. Nanomaterials for effective drug delivery to skin conditions such as AD have attracted a lot of attention owing to its ability to encapsulate, protect, and release the cargo at the diseased skin site. However, there are lots of unmet challenges especially in terms of development of non-toxic formulations and clinical translation of established nanomedicines in the form of accessible products. Numerous formulations have emerged as carrier for poorly soluble and permeable drugs, viz., lipidic, polymeric, metal, silica, liposomes, hydrocarbon gels and this field is evolving. This review is intended to provide an insight incidences associated with pathophysiology of AD and challenges with existing treatments of AD. Focus is kept on reviewing current development and emerging nanomedicines for effective treatment of AD. The review also inculcates merits of several nanomedicines in overcoming challenges of existing products and its future implications.

Indexed as

NanomedicineAnimalsClinical Trials as TopicDermatitis, AtopicDrug CompoundingEmulsionsHumansMicellesNanoparticlesEmulsionsMicellesatopic dermatitisnanomedicinesnovel formulationsskin targetingtopical drug delivery

Identifiers

PMID33486609
PMCPMC7828097
OpenAlexW3124876945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.